Asthma | Access & Reimbursement | US | 2023

Market outlook

The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GlaxoSmithKline’s Advair, AstraZeneca’s Symbicort) will likely decline further as new generic / branded generic agents continue to launch. In addition, the entrance of LABA/LAMA/ICS FDCs will create uptake challenges for Boehringer Ingelheim’s Spiriva. A novel biologic (Amgen / AstraZeneca’s tezepelumab) could compete with existing asthma biologics (e.g., GSK’s Nucala, AstraZeneca’s Fasenra) for certain subpopulations with severe refractory asthma. The entry of a novel SABA/ICS FDC could affect the uptake of SABA reliever therapies, especially among patients with mild / intermittent asthma. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging asthma agents will face increasing challenges as they strive to retain/gain favorable formulary position and market uptake.

Questions answered    

•Which key asthma therapies (e.g., Roche / Novartis’s Xolair, Sanofi / Regeneron’s Dupixent) have favorable formulary placement, and how do payers manage the use and costs of these therapies?

•How do reimbursement restrictions affect physicians’ prescribing of LABA/ICS FDCs, Spiriva, Trelegy, and biologics to their asthma patients?

•How do payers / physicians expect emerging branded and generic / branded generic versions of market-leading LABA/ICS FDCs (e.g., AB-rated generics of Advair and Symbicort) and other inhaled therapies to affect access to / prescribing of current branded therapies?

•How do physicians anticipate using emerging biologics, SABA/ICS FDCs (i.e., AstraZeneca’s PT-027 [albuterol / budesonide FDC]), and LABA/LAMA/ICS FDCs (i.e., AstraZeneca’s Breztri), and how do payers expect to cover these therapies on commercial plans?

Product description

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment.  Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.